# Sight Sciences Inc. (SGHT) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $8.35, market value $460 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Sight Sciences Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 5.5×**. Each dollar of revenue is priced at 5.5×.
- **Price / book: 8.6×**. The shares trade at 8.6× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -5.1%** (5-yr avg -12.7%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Gross margin: 88.0%**. Sight Sciences Inc. keeps 88.0% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: -33.4%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -49.7%**. The company reported a net loss over the last twelve months.
- **Return on equity: -60.1%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -179.4%**. Return on all capital, debt included, is -179.4%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -25.8%**. Each dollar of assets produces -25.8% of profit.

## Growth
- **Revenue growth (1 yr): -3.1%** (3-yr 2.7%/yr, 5-yr 22.9%/yr). Revenue fell 3.1% over the last year, against 22.9% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 28.2%**. Earnings per share rose 28.2%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 0.63**. Debt is 0.63 times equity, moderate leverage.
- **Net debt / EBITDA: 1.9×**. It would take 1.9 years of operating earnings to repay net borrowings, within the comfortable range.
- **Altman Z-score: 5.76**. A Z-score of 5.76 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Sight Sciences Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 123.9%** (YTD 5.3%, 3-mo 87.6%). The shares are up 123.9% over twelve months including dividends.
- **From 52-week high: -9.6%** (161.8% above the low). Trading 10% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 66**. An RSI of 66 is neutral.
- **Beta (1 yr): 1.91** (volatility 84%). Beta of 1.91 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=SGHT · Page: https://foliofundamentals.com/stocks/sght

Not investment advice.